[Lofepramine: a comparative clinical study with amitriptyline].

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Research

Background:

• Lofepramine is a novel tricyclic antidepressant with a favorable pharmacological profile.
• It exhibits low toxicity, reduced anticholinergic effects, and good tolerance compared to other tricyclic antidepressants.
• High plasma concentration levels and efficient elimination are noted.

Purpose of the Study:

• To compare the efficacy and side-effect profile of lofepramine with amitriptyline.
• To evaluate therapeutic response in patients with depression using a double-blind study design.

Main Methods:

• A double-blind study involving 60 outpatients (5 male, 55 female) aged 16-65 with endogenous or neurotic depression.
• Equimolar dosages of lofepramine and amitriptyline were administered.
• Statistical analysis using the chi-square test was performed on therapeutic response, Hamilton Depression Rating Scale scores, depression type, and side-effects.

Main Results:

• No statistically significant differences were found between lofepramine and amitriptyline in maximal therapeutic response or Hamilton Depression Rating Scale scores.
• Xerostomy (dry mouth) was a noted side-effect, occurring less frequently with lofepramine.
• Lofepramine demonstrated a trend towards better outcomes in neurotic depression.

Conclusions:

• Lofepramine demonstrates comparable therapeutic efficacy to amitriptyline in the studied outpatient population.
• Lofepramine appears to be a potentially better option for patients with neurotic depression and those sensitive to anticholinergic adverse effects.
• Further research may be warranted to confirm these trends.